An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A quick new result: a drug called tradipitant reduced vomiting caused by semaglutide in a Phase 3 clinical trial. In plain terms, people taking semaglutide — a weight-loss and diabetes medicine that often makes some people feel sick — had less vomiting when tradipitant was added. The announcement comes from the company or the trial report and focuses on this specific side effect. Semaglutide is the active ingredient in products like Ozempic and Wegovy. It works by copying a natural gut hormone that helps control appetite and slows how fast your stomach empties, which can make you feel fuller and eat less. That same stomach-slowing and brain-signaling effect is why some people get nausea, vomiting, or other stomach troubles when they start the drug or increase the dose. The new study was a Phase 3 trial, which means it involved people and is one of the late-stage tests before a drug might get wider approval for a use. According to the report, adding tradipitant cut the amount of vomiting tied to semaglutide. The headline doesn’t say how many people were in the trial, how big the reduction was (for example, percentage points or number of events), or whether other symptoms like nausea were also improved. Because I only have the headline and short snippet, I can’t tell you the exact size of the benefit, how long it lasted, or whether the effect was statistically strong. Why this could matter: semaglutide and similar drugs are widely used for diabetes and weight management, but their stomach side effects are a real barrier for some patients. If tradipitant reliably reduces vomiting, more people might tolerate semaglutide better and stay on the treatment. That could mean better diabetes control or more successful weight-loss efforts for those who otherwise stop because of side effects. But there are important caveats. Tradipitant itself can have side effects and would need regulatory approval for this specific combination or use; a positive Phase 3 result is promising but not the same as full approval. We also don’t know long-term safety when the two drugs are used together, whether tradipitant affects semaglutide’s weight-loss or glucose effects, or which patients benefit most. If you’re on semaglutide and struggling with vomiting, don’t start or stop medications based on a headline — talk to your doctor, who can weigh the evidence and consider approved options. Bottom line: a late-stage trial suggests tradipitant may reduce semaglutide-related vomiting, but we need the full trial details and regulatory review before changing care.
Source: HCPLive